-
Research Frontier Polygenic risk scores combined with family history of cancer are more conducive to identifying people at high risk of death from prostate cancer
Time of Update: 2022-11-01
Research methodsThe study included data from 10,120 patients in the Health Professionals Follow-up Study (HPFS) to assess their family history of prostate cancer or breast cancer, and combined with PRS scores (including 269 prostate cancer variants) to identify men at risk of prostate cancer and prostate cancer-specific death at different ages.
-
Cell Journal (IF=17) Zu Xiongbing's team at Central South University discovered a safe and effective combination therapy for the treatment of muscle-invasive bladder cancer
Time of Update: 2022-11-01
Immune checkpoint blockade (ICB), including anti-PD-1/PD-L1, has shown promising survival benefits and revolutionized the status quo of treatment for patients with advanced MIBC.
Original link: #—END—content is 【iNature】 Immune checkpoint blockade (ICB), including anti-PD-1/PD-L1, has shown promising survival benefits and revolutionized the status quo of treatment for patients with advanced MIBC.
-
Is there also a gender difference in the prognosis of "evidence-based medicine" urothelial carcinoma?
Time of Update: 2022-11-01
Research methodsThe investigators searched the PubMed, Web of Science, and Scopus databases and considered studies eligible if they involved comparisons of overall survival (OS), tumor-specific survival (CSS), disease progression, and recurrence-free survival in NMIBC/MIBC patients.
-
"Evidence-based medicine" Asians are more likely to benefit from zoledronic acid?
Time of Update: 2022-11-01
Fig. 1 OS forest plot of patients in the ethnic subgroupEffect of ZA on SRE in PCa patientsZA significantly reduced the incidence of SRE compared to the control group (OR=0.
-
Clinical necessity Consensus on the safety of clinical application of urothelial carcinoma antibody conjugate drugs
Time of Update: 2022-11-01
Table 1 Recommended ADC drug guidelines for advanced urothelial carcinoma>>>>Pre-medication evaluation and contraindications(1) Adverse reactions related to ADC drug treatment can affect multiple organs of the body, and due to the different antibodies and cytotoxic drugs, there are differences between the spectrum of adverse drug reactions.
-
Research frontiers Safety outcomes of the TALAPRO-1 study
Time of Update: 2022-11-01
Fig. 1 Levels of TEAEs occurring in the safety population (A: Comprehensive; B: Hematology TEAEs; C: Non-hematology TEAEs)Hematology TEAEs usually occur in the 4-5 months of treatment start, the median duration of grade 3/4 hematology TEAEs such as anemia, neutropenia, and thrombocytopenia is usually 7-12 days, and patients do not experience grade 4 anemia or neutropenia events.
-
Clinical Essentials Guidelines for the diagnosis and treatment of premature ejaculation
Time of Update: 2022-10-26
)Editor: Wang Mumu Review: LR Execution: Wang MumuTreatment of premature ejaculation includes medication, behavioral therapy, psychosexual interventions, and comprehensive treatment should receive more attention to improve efficacy and adherence.
-
Clinical necessity Chinese expert consensus on the diagnosis and treatment of male stress urinary incontinence
Time of Update: 2022-10-26
GuideMale urinary incontinence is caused by urinary sphincter and/or bladder dysfunction caused by involuntary leakage of urine from the urethra, usually divided into stress urinary incontinence (SUI)
-
Research Frontiers Young men pay attention! If you suspect you have chronic prostatitis, seek medical attention as soon as possible!
Time of Update: 2022-10-25
GuideProstatitis is one of the most common diseases in urology, with a lifetime prevalence of about 9%. Given the insidious and diverse symptoms of chronic prostatitis (CP), the diagnosis of CP is dif
-
The authors interpret the regulation of histone modification status and improve the embryonic development efficiency of round sperm injection: Zhao Xiaoyang/Chang Gang/Li Lin collaborated to discover a new strategy to optimize male infertility assisted reproductive technology
Time of Update: 2022-10-21
Welcome to pay attention to the official scientific public accountClick "Read Original" below to access the full paperLight up your praise for Chinese scientific researchFor epigenetic modification defects in the prokaryotic period of ROSI embryos, the researchers screened 178 related small molecule compounds and found that the small molecule inhibitor A366 of G9A (EHMT2) was able to increase the blastocyst development rate and live birth rate of mouse ROSI embryos by about two times.
-
In localized prostate cancer, how to choose external beam radiation therapy and radical prostatectomy? 5 years follow-up data for your reference
Time of Update: 2022-10-21
Edit: LRReview: LRExecution: LRAfter 5 years of follow-up, the study found that patients in the EBRT-LDR group had more severe urinary irritation/obstruction, worse bowel function, but less urinary incontinence symptoms compared with RP.
-
Research frontiers EV combined with pembrolizumab are expected as first-line treatment for advanced urothelial cancer
Time of Update: 2022-10-21
Edit: LRReview: LRTypesetting: LRGuideCisplatin-based combination chemotherapy is the standard of care (Ia/mUC) for locally advanced or metastatic urothelial carcinoma, but there are still problems such as toxicity, insufficiently durable response, and incompatibility in some patients.
-
First to be confirmed: an epigenetic drug EZH2 inhibitor that treats bladder cancer by activating the immune system
Time of Update: 2022-10-21
The study is the first to confirm that Tazemetostat, an epigenetic drug currently used to treat lymphoma and sarcoma, is able to suppress bladder cancer by activating the immune system。 The research team has initiated human clinical trials for advanced bladder cancer.
-
Research frontier Prostatic hyperplasia patients for several years of "male" words can be solved in 10 minutes? The results of a multicenter study of minimally invasive therapy Rezum were announced
Time of Update: 2022-10-20
Research backgroundThe Rezum system is one of the latest minimally invasive surgical treatments for BPH, but data on urinary and sexual outcomes and complications are lacking.
Research backgroundThe Rezum system is one of the latest minimally invasive surgical treatments for BPH, but data on urinary and sexual outcomes and complications are lacking.
-
Research frontiers in this together! The MDT model helps the diagnosis and treatment of metastatic prostate cancer
Time of Update: 2022-10-20
Editor: Mumu WangReview: LRExecution: Wang MumuIn recent years, the preferred treatment for patients with metastatic prostate cancer (mPC) has shifted from androgen deprivation therapy (ADT) alone to ADT combination.
-
Enfortumab vedotin combined with pembrolizumab is expected to become the first-line treatment for advanced urothelial carcinoma
Time of Update: 2022-10-20
Fig. 3 DOR, progression-free survival (PFS), and OS results of patientsconclusionEV plus pembrolizumab is a 1L platinum-free regimen that has shown encouraging antitumor activity and a controlled safety profile in patients with Ia/mUC who are not eligible for cisplatin, even in patients with liver metastases.
-
Standardize the diagnosis and treatment process of prostate diseases Provide patients with full management services for patients, the 18th International Conference on Cyberpathology, Prostate Disease Forum, Professor Liao Yongbin's interview
Time of Update: 2022-10-14
"For the treatment strategy of prostatic hyperplasia, Liao Yongbin stressed, "The combination of traditional Chinese medicine and western medicine can not only improve the symptoms in time, but also protect the bladder function and kidney function, and improve the quality of life of patients.
-
Philippine Long Vision - 2022 ESMO Perspective: Peer Phase "Benefit", Exploring the New Development of ADT Combination Treatment and Predictive Biomarkers for Prostate Cancer
Time of Update: 2022-10-14
The "beacon" under accurate diagnosis and treatment, biomarkers guide the prognosis of the diseaseThe ESMO conference presented the results of a post-mortem analysis of the PEACE-1 Phase III study, which evaluated the association between 8-month PSA and imaging progression-free survival (rPFS) and OS in patients treated with abiraterone.
-
PSA depth rapidity, OS long-term "coerc" stage, ADT+ apatamide combination therapy for mHSPC patients to win the chance of survival in classic cases
Time of Update: 2022-10-14
*For medical professionals onlyClassic case sharing ~The following two patients are both cases of metastatic hormone-sensitive prostate cancer (mHSPC), and both were treated with apatamide + androgen deprivation therapy (ADT) after a definitive diagnosis, and the PSA dropped below 0.
-
Hot News Optimize metabolism and help PC health - fasting simulated diet
Time of Update: 2022-10-14
0001) than in patients with baseline systolic blood pressure Figure 1 Changes in metabolic risk factors in PC patients (compared to baseline)Conclusion of the studyThe results of this pilot study showed that the application of periodic FMD in PC patients had good safety and that overall patient compliance was high (83%).